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Efficacy of SpayVacW as a Contraceptive in
Feral Horses
JAMES E. ROELLE,1 U.S. Geological Survey, Fort Collins Science Center, Fort Collins, CO 80526, USA
STEPHEN S. GERMAINE, U.S. Geological Survey, Fort Collins Science Center, Fort Collins, CO 80526, USA
ALBERT J. KANE, U.S. Department of Agriculture, Animal and Plant Health Inspection Service, Fort Collins, CO 80526, USA
BRIAN S. CADE, U.S. Geological Survey, Fort Collins Science Center, Fort Collins, CO 80526, USA

ABSTRACT We tested the efficacy of 2 formulations of the immunocontraceptive SpayVac1, which

packages the immunogen porcine zona pellucida (PZP) and an adjuvant in multilamellar liposomes, as a
contraceptive in captive feral horses (Equus caballus) for 3 consecutive breeding seasons (Pauls Valley, OK,
USA; 2012–2014) following a single inoculation. Annual fertility rates in control adult female horses (n ¼ 30
each yr) were 100%, 96.7%, and 100%. In the nonaqueous treatment group, fertility was 16.7% in the first
year (n ¼ 30) and 75.9% in the second year (n ¼ 29), at which point we dropped the group from the study.
Fertility rates in the aqueous group were 13.3%, 46.7%, and 43.3% (n ¼ 30 each yr). Fifteen of the females in
the aqueous group were infertile in all 3 years. Across 11 sampling dates postvaccination, mean PZP antibody
titers in serum were 33.7–91.9% greater in nonpregnant females than pregnant females for the aqueous
treatment group and 7.8–82.8% greater for the nonaqueous group. However, the 15 consistently infertile
females did not necessarily have the greatest antibody titers. Reactions at the injection site occurred in 29.8%
of the 84 females that received an injection other than saline solution, but there was no evidence that the
reactions were painful or affected mobility. The nonaqueous formulation produced more local reactions than
did the aqueous, but presence of PZP did not increase the frequency of reactions above that seen with
liposomes þ adjuvant. Uterine edema was not found at frequencies greater than would be expected in
untreated females. Additional research to explore relationships between vaccine dose, adjuvant, and efficacy is
warranted. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
KEY WORDS Equus caballus, feral horse, fertility control, immunocontraception, porcine zona pellucida, SpayVac1,
wildlife contraception.

Feral horse (Equus caballus) populations managed by the
Bureau of Land Management (BLM) in the western United
States often grow rapidly and, in the absence of intervention
by BLM, would frequently exceed the carrying capacity of
their ranges (Eberhardt et al. 1982, Garrott et al. 1991b,
Roelle et al. 2010). The BLM has most often controlled herd
size through a gather (round up) and removal process,
offering excess horses to the public for adoption. Over time,
the supply of horses has exceeded adoption demand, and
BLM has moved thousands of animals to long-term holding
pastures where they are cared for as long as they live at
considerable expense to American taxpayers. In 2007, for
example, the cost of holding animals off the range was
approximately US$21 million, or about 67% of the budget for
BLM’s Wild Horse and Burro Program (U.S. Government
Accountability Office 2008:9).
The BLM has long been interested in fertility control as a
means of regulating feral horse reproduction and partial
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solution to the problem of escalating off-range holding costs.
The most promising fertility control agents to date are based on
porcine zona pellucida (PZP) glycoproteins extracted from pig
(Sus scrofa) ovaries. When injected into mammalian species
such as the horse, these proteins induce production of
antibodies that bind to the surface of the ovum and block sperm
penetration and fertilization (Liu et al. 1989). Possible effects
on ovarian function have been noted as well (Kirkpatrick et al.
1992, Bechert et al. 2013). The most widely used form of PZP
available at the present time is an emulsion registered as
ZonaStat-H by the U.S. Environmental Protection Agency
for use in horses and burros (E. asinus). Unfortunately,
ZonaStat-H has 2 important drawbacks relative to use in BLM
herds. First, a booster inoculation is required, ideally 3–4 weeks
after the primer is administered (Liu et al. 1989). Because
darting is rarely feasible on western rangelands, most BLM
herds must be gathered in order to provide access to the horses
for inoculation. Female horses would need to be held in
captivity long enough to administer a booster 3–4 weeks later.
Second, ZonaStat-H has a reported duration of efficacy of only
7–10 months, after which annual booster inoculations are
required to maintain infertility (Liu et al. 1989, Kirkpatrick
et al. 1990, Lyda et al. 2005). Some progress in overcoming
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these drawbacks has been made by substituting time-release
pellets, delivered at the same time as the primer injection, for
the booster at 3–4 weeks and first annual booster. This
formulation, sometimes referred to as PZP-22, has a reported
efficacy of 22 months (Turner et al. 2007), but this is still less
than ideal from the BLM’s perspective.
A third formulation of PZP known as SpayVac1, produced
by ImmunoVaccine Technologies Inc. (IVT; Halifax, NS,
Canada) using a proprietary liposome technology, has been
reported as having long-term, single-dose efficacy in several
species, including grey seals (Halichoerus grypus; Brown et al.
1997a), fallow deer (Dama dama; Fraker et al. 2002), and
most recently feral horses (Killian et al. 2008, Fraker and
Brown 2011). Killian et al. (2008), for example, reported
contraceptive efficacy of 100%, 83%, 83%, and 83% in 4 years
following inoculation of 12 feral horses in Nevada, USA,
with SpayVac. This result sparked renewed interest within
the BLM to conduct further investigations on the efficacy of
SpayVac in feral horses.
The 3 main objectives of our study were to 1) quantify the
efficacy of SpayVac in preventing pregnancy and foaling over a
maximum of 5 breeding seasons postinjection when females
are exposed to breeding males in a pasture setting; 2) determine
the relationship between PZP serum antibody titers and
fertility; and 3) assess the frequency and severity of injectionrelated and general side effects, if any, following intramuscular
injection by hand. In addition, for the 4 years of their study,
Killian et al. (2008) reported that 70–100% of females treated
with SpayVac showed some degree of uterine edema.
Although we do not view uterine edema as a serious
contraindication, others have indicated concern, so a fourth
objective was to estimate the frequency and degree of uterine
edema in females treated with SpayVac. Finally, Bechert et al.
(2013) reported that 93% of females that they treated with
SpayVac ceased estrous cycling within 3–4 months after
vaccination. Our fifth objective was therefore to determine
what proportion of our SpayVac-treated females stopped
cycling.

STUDY AREA
We conducted our captive breeding trial at BLM’s wild horse
and burro adoption facility near Pauls Valley, Oklahoma,
USA. Adult female horses resided year-round in 3 pastures
of approximately 12 ha each, and were accompanied by
breeding males from approximately the first week in June
(2011) or the first week in May (2012 and 2013) to the first
week in October (all years). During the remainder of the
year, space limitations forced us to house the males in a
separate facility in Nebraska, USA. We transported males to
and from their winter quarters by trailer, moving them back
to Oklahoma in the spring 2–3 weeks before beginning the
breeding trial for that year. We immunized the females and
drew blood samples in a processing facility consisting of a
series of alleys and pens and a padded hydraulic squeeze
chute located 100–300 m from the pastures.
Horses fed on pasture bermudagrass (Cynodon sp.) ad
libitum and alfalfa hay provided at a rate of approximately
6.4 kg/animal/day. FlaxLic1 protein/fat supplement (New
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Generation Feeds, Belle Fourche, SD, USA) and Ranch
House trace mineralized salt blocks (United Salt Corporation, Houston, TX, USA) were also provided ad libitum.
Bureau of Land Management personnel annually immunized horses against eastern and western equine encephalomyelitis, equine influenza type A2, the EHV-1 and EHV-4
strains of equine herpes virus, and tetanus (Fluvac Innovator1 5; Zoetis, Florham Park, NJ, USA); West Nile virus
(Vetera1 WNV; Boehringer Ingelheim Vetmedica, St.
Joseph, MO, USA); Streptococcus equi (Strepvax1 II;
Boehringer Ingelheim Vetmedica); and rabies (Imrab1 3;
Merial Limited, Duluth, GA, USA). Additionally, BLM
personnel dewormed horses at least annually (more frequently
for specific susceptible individuals) using IvermaxTM Equine
Oral Liquid (RXV Products, Westlake, TX, USA).

METHODS
Vaccine Preparation
We conducted all work on this study under the auspices of a
protocol (#2011-06) approved by the Animal Care and Use
Committee at the Fort Collins Science Center, U.S.
Geological Survey, Fort Collins, Colorado, USA. We chose
2 formulations of SpayVac (an aqueous emulsion and a
nonaqueous form) for testing based on a recommendation
from a companion study on safety and mechanism of action
conducted at Oregon State University, Corvallis, Oregon,
USA (Bechert et al. 2013). Personnel at IVT prepared the
vaccines as described by Brown et al. (1997b). Briefly, they
obtained frozen pig ovaries from SiouxPreme Packing Co.
(Sioux Center, IA, USA) and isolated PZP by grinding thawed
ovaries and passing the resulting mixture through a series of
nylon mesh screens with successively decreasing pore sizes to
recover oocytes. They then homogenized the oocytes to release
PZP, mixed the PZP at a rate of 200 mg/dose with phosphate
buffered saline (pH ¼ 7.4), and added 0.2 g lecithin and 0.02 g
cholesterol (Lipoid, Newark, NJ, USA) per dose to form
multilamellar liposomes. One half of the PZP-liposome
mixture was added to Modified Freund’s Adjuvant (MFA;
Calbiochem, San Diego, CA, USA; 1:1 v/v) to form a waterin-oil emulsion (the aqueous vaccine; 1 mL/dose). The second
half of the PZP-liposome mixture was lyophilized and then
reconstituted with MFA to form the nonaqueous vaccine
(0.5 mL/dose). Vehicle controls were produced in the same
manner but without the PZP antigen. Saline controls consisted
of 1 mL of phosphate-buffered saline. Technicians at IVT
loaded all vaccines and control doses into individual syringes
and delivered them to us frozen on dry ice.
Treatments and Blood Sampling
We randomly selected 90 females—ages 4 (n ¼ 68), 5
(n ¼ 18), 6 (n ¼ 2), or 7 (n ¼ 2)—from 120 females that were
present at the Pauls Valley facility when we initiated our
study. All females were thus at or near prime breeding age
(Garrott et al. 1991a, Roelle et al. 2010), and all were open
(nonpregnant) at the time of enrollment by virtue of
separation from males during the previous breeding season.
Age was either known precisely (i.e., removed from the range
as a foal or born in captivity) or estimated by tooth eruption
Wildlife Society Bulletin
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and wear (American Association of Equine Practitioners
2002). Bureau of Land Management personnel uniquely
marked each female on the left hip with a 4-digit freeze mark
in numerals 7.6 cm high. We assigned each female to 1 of 3
experimental groups (aqueous vaccine, nonaqueous vaccine,
and control) in a stratified-random fashion such that each
group was equally represented in each of the 3 pastures. We
further subdivided the 30 females in the control group into
aqueous (4 F/pasture), nonaqueous (4 F/pasture), and saline
(2 F/pasture) groups. After allowing all materials to thaw for
approximately 30 min at room temperature, we delivered
vaccines and sham doses on 30 March 2011 by hand injection
in the left rump while each female was restrained in a padded
hydraulic squeeze chute.
At the time of vaccination and on 7 additional occasions in
2011 (3 May, 7 Jun, 6 Jul, 2 Aug, 7 Sep, 5 Oct, and 14 Dec),
we drew 10 mL of blood from each female in serum separator
vacutainers by jugular venipuncture for PZP titer assays. We
also drew blood samples on 7 March 2012, 9–10
January 2013, 6 March 2013, and 13–14 November 2013.
Following collection, we allowed the blood samples to clot
for approximately 2 hr at room temperature. We then
centrifuged the samples at 1,300 G for approximately 12 min
and removed 2 aliquots of approximately 2 mL of serum by
pipette. We placed each aliquot in a 10-mL polypropylene
transport vial labeled with the date and horse identification
number, froze the samples overnight in a household freezer,
and shipped them on dry ice to Fort Collins, Colorado,
where they were stored at 808 C until being shipped on dry
ice by overnight courier for titer assays.
To corroborate our foaling observations (see below), we
drew an additional 10 mL of blood from each female in a
plain red-top vacutainer on 12 December 2011, 9–10
January 2013, and 13–14 November 2013. We separated
serum from these samples as described above and shipped the
frozen samples to the Endocrinology Lab, Animal Health
Diagnostic Center, Cornell University, Ithaca, New York,
USA, for pregnancy testing. Personnel at the lab assayed the
samples for pregnant mare serum gonadotropin and estrone
sulfate and characterized each female as open, pregnant, or
inconclusive.
Female Horse Health and Condition
During each blood draw through 7 March 2012, we observed
females carefully for general health and palpated each injection
site to ascertain whether a reaction had occurred. We
characterized each site as follows: none ¼ no reaction apparent;
swelling ¼ a diffuse raised area, perhaps irregular in shape, may
be firm, but does not appear or feel hard; lump ¼ a distinct,
roughly circular nodule that appears or feels hard; abscess ¼ a
draining sore or pocket of fluid or pus. We characterized the
severity of each reaction on a scale from 0 to 3, using the same
scoring system both in palpation of the injection sites and
pasture observations (see below): 0 ¼ no reaction observable or
palpable; 1 ¼ reaction (swelling, lump, or abscess) present, but
no pain or lameness noticeable; 2 ¼ reaction present, mild to
moderate lameness or response to palpation; 3 ¼ reaction
present, severe lameness or strong response to palpation. On 30
Roelle et al.
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March 2011 and 7 March 2012, we also estimated body
condition of our females using the system of Henneke et al.
(1983). We assigned each female a score from 1 to 9 following
observation in the chute and palpation of fat and soft tissue of
the neck, back, ribs, and rump.
Serum Assays
Technicians at IVT used an enzyme-linked immunosorbent
assay to determine PZP antibody titers in horse serum. They
coated 96-well polystyrene microtiter plates (Bio-Rad,
Hercules, CA, USA) with PZP antigen (prepared in-house,
1 mg/mL) and incubated them overnight at 48 C. They then
washed the plates with a Tris wash buffer (Tris-buffered saline/
Tween-20) and blocked them with 3% gelatin (Bio-Rad) for
30 min at 378 C. Following another wash, they added a
standard horse serum sample and unknown horse sera samples
to the wells and incubated the plates at 48 C overnight. They
diluted unknown serum samples and a positive reference serum
sample to 1/25,000 and added each sample to the plates in
triplicate. They then washed the plates, added a secondary
antibody, Protein G (Calbiochem) conjugated to alkaline
phosphatase enzyme, to each well at a dilution of 1/1,000, and
incubated the plates for 1 hr at 378 C. Following another
wash, they incubated the plates for 1 hr at 378 C with a
substrate solution containing 4-nitrophenyl phosphate disodium salt hexahydrate (Sigma–Aldrich Chemie GmbH,
Buchs, Switzerland) at a concentration of 1 mg/mL. They
then used a microtiter plate reader (ASYS Hitech GmbH,
Eugendorf, Austria) to measure the optical density or
absorbance of each well at a wavelength of 405 nanometers.
They calculated titers of the unknown serum samples as the
average absorbance of the triplicate unknown samples
expressed as a percentage of the average absorbance of the
triplicate positive reference sample. The positive reference
sample was from a female previously vaccinated (in a separate
study) with SpayVac and determined to have a strong, PZPspecific antibody response. The positive reference sample was
considered to have a titer of 100%.
Male Horses
We randomly selected 12 adult males, 6–9 years of age at the
start of the study, from a group gathered at the Adobe Town/
Salt Wells Creek herd management complex in Wyoming,
USA, in October 2010. We gelded and dropped 1 of these
males from the study because of his aggression. We allowed
2 months following inoculation for anti-PZP antibody titers
to build and introduced 3 randomly selected males into each
pasture with the females on 7 June 2011. We anticipated that
the pastures would be large enough for each male to acquire a
stable harem from the 30 females present and coexist with
minimal aggression, but this turned out not to be the case.
Fighting was not uncommon, and in 2 of the pastures
breeding activity was dominated by a single male. On 6
July 2011, we randomly assigned a single male to each pasture
and developed a random rotation such that pastures received
a new male approximately every 2 weeks, and all males had a
rest period of 2 weeks following each session in a pasture.
Following the first rotation, we eliminated another male
because he was never observed breeding a female. In 2012
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and 2013, we used a new randomly assigned order each year
and each pasture session lasted approximately 3 weeks. Two
males died of causes unrelated to the study, one due to
impaction and rupture of the large colon and the other due to
a spinal injury, during the winter of 2012–2013, leaving only
8 in the rotation in 2013.
Pasture Observations
A technician who was blind to the treatment status of
individual females observed each pasture 2 hr/day and 3
days/week to record information on injection-related (2011
only) or other health issues, estrous and breeding behavior, and
foaling. We tried several vantage points or modes of
transportation (e.g., from the fence surrounding the pasture,
from a truck in the pasture, mounted on a domestic horse) for
making these observations, ultimately settling on a golf car as
the best platform; using the car, we were able to move within a
few meters of the females while evoking little reaction other
than curiosity. We recorded the nature and severity of reactions
to the injections using the system described above. We
characterized estrous and breeding behavior on a scale from 0
to 5 as follows: 0 ¼ no evidence of estrous or breeding behavior
observed; 1 ¼ warm ¼ squatting, winking, or urination observed, but female is not completely receptive to the male;
2 ¼ hot ¼ squatting, winking, or urination observed and
female is receptive to the male; 3 ¼ mounting observed;
4 ¼ penetration observed; and 5 ¼ ejaculation (flagging of the
male’s tail) observed. The main purpose of these observations
was simply to ensure that females were being bred. We
associated foals with individual dams based on nursing by the
foal that was readily accepted by the female and protective
behavior by the female, especially during the first few days and
weeks of the foal’s life. Female–foal pairings were observed 3
times/week from birth through the end of the breeding season.
Uterine Edema
On 9–10 January 2013 and 13–14 November 2013, we
examined each female in the study per rectum using a
Universal Medical Systems 900 (Bedford Hills, NY, USA)
portable ultrasound and a 5-MHz linear transducer. Uterine
edema was characterized as none, slight, moderate, or
extensive. During these examinations, we also recorded
information on follicular development, stage of estrous cycle,
and pregnancy. All examinations were performed while
females were restrained in a squeeze chute; none required
sedation.
Cyclicity
On 3 June, 10 June, 17 June, 23 June, and 1 July 2014, we
drew 10-mL samples of blood in a plain red-top vacutainer
from each female treated with the aqueous formulation of
SpayVac. We extracted serum as previously described and
shipped it to the Endocrinology Lab, Animal Health
Diagnostic Center, Cornell University for progesterone
analyses. Females with <0.5 ng/mL progesterone in all 5
samples were considered to be not cycling.
Analyses
We had the following information available for assessing
drug efficacy: foal observations (2012 and 2013), palpation
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and ultrasound (2013 and 2014), and hormonal pregnancy
tests (all 3 yr). In the hormonal pregnancy tests, there were 20
cases where the results were inconclusive; in 18 of those 20
cases, no foal was observed. It thus seemed important to
include those cases in our analyses, by using the other 2
criteria, to obtain the best estimate of drug efficacy. We
therefore performed all of our analyses on a composite
outcome measure in which a female was judged to be fertile if
any of the 3 criteria (ultrasound, hormone test, foal
observation) was positive. Use of this composite measure
allowed us to include females whose hormone assays were
inconclusive, but likely had only a small effect on our overall
results, because results from the various measures of fertility
were in complete agreement in 220 (92.1%) of 239 cases. We
also performed duplicate analyses (data not shown) using
only the results of hormonal pregnancy testing (because data
were available for all 3 yr); in no case did the results differ
substantively from those presented here for the composite
measure of fertility.
We compared the binomial composite measure of fertility
across the 2 treatment groups (aqueous and nonaqueous)
with logistic regression when we were interested in
estimating treatment group differences after adjusting for
effects of years since treatment, body condition, and pasture
assignment. We did not include female age in our models,
but rather controlled for the effects of age through
randomization and restricting enrollment to females 4–7
years of age. We used Akaike’s Information Criterion (AIC;
Burnham and Anderson 2002) to select those models better
supported by the data. Because control females were fertile in
89 of 90 possible instances, the logistic model estimates were
limited to comparisons of aqueous and nonaqueous groups.
We also compared fertility in the control group with each of
the treated groups without any additional covariates using
Fisher’s exact tests for the homogeneity of proportions fertile
in each year. Comparisons of 2 treatment groups with
Fisher’s exact test provided a corresponding 95% confidence
interval on the odds ratio. In addition, we compared
injection-site reactions across the control and treatment
groups, and by formulation (aqueous vs. nonaqueous, treated
and control females combined) and ingredient (liposomes
plus adjuvant with PZP or without PZP, treated and control
females combined) with logistic regression and Fisher’s exact
test for homogeneity of proportions.

RESULTS
There was the potential for females in the control group to be
fertile in 90 cases (30 F  3 yr) during the course of our study.
Using the composite measure, fertility occurred in 89 cases,
indicating that males were able to cover females adequately
with the rotation schedules that we used. Thus, differences in
pregnancy rate or composite fertility rate between control
and treatment groups can likely be attributed to the
treatment, rather than to a failure of the males to breed.
The aqueous formulation of SpayVac was effective in 2012
as evidenced by a fertility rate of only 0.133 foals/female as
compared with 1.00 foals/female in the control group (odds
ratio 95% CI ¼ [29.8, 1], P < 0.001; Table 1). Fertility in
Wildlife Society Bulletin
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Table 1. Fertility rates in treated and control adult female feral horses enrolled in a captive breeding trial of the immunocontraceptive SpayVac at Pauls
Valley, Oklahoma, USA, 2012–2014.
Aqueousa

Nonaqueousa

Year

Fertility rate

n

P

2012
2013
2014

0.133
0.467
0.433

30
30
30

<0.001
<0.001
<0.001

b

c

n

b

Fertility rate
0.167
0.759

30
29
Withdrawn

Control
P

c

Fertility rateb

n

1.00
0.967
1.00

30
30
30

<0.001
0.026

a

Aqueous and nonaqueous refer to 2 formulations of SpayVac.
Fertility rate is expressed as proportion of females. Fertility was determined through hormone assay (pregnant mare serum gonadotropin and estrone sulfate),
rectal palpation and ultrasound, and direct observation of foals. A female was considered fertile if any of the 3 measures was positive.
c
P-value is the probability that the fertility rate is the same in the treatment and control groups as determined by Fisher’s exact test.
b

Roelle et al.
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between antibody titer and fertility in individual females
was less clear (Table 3). Female number 609, for example,
had a maximum titer of 60.11%, was not one of the females
that ceased cycling postvaccination, and did not become
pregnant in any of the 3 years of our study, whereas several
females with greater maximum titers did become pregnant.
None of the 6 females that received saline control
inoculations exhibited any reaction at the injection site
(Table 4). Of the 84 animals that received either SpayVac or
the liposomeþadjuvant control doses, 25 (29.8%) exhibited a
reaction of some kind (swelling, lump, or abscess). Abscesses
were present in 5 (6.0%) of the 84 during the year in which
we monitored the injection sites; all 5 occurred in animals
that received either the nonaqueous vaccine or the
nonaqueous control injection. Abscesses appeared as early
as 2 months postinoculation and as late as 5 months; some
healed only to reappear at a later date. On female 3425, for
example, an abscess was first recorded on 7 September 2011,
was recorded again on 5 October, had disappeared by 14
December, and reappeared by 7 March 2012. In no case,

PZP titer (% of positive reference value)

the aqueous group increased in 2013, but remained different
from rates in the control group (odds ratio 95% CI ¼ [4.1,
1,424.5], P < 0.001), which also occurred in 2014 (odds ratio
95% CI ¼ [7.7, 1], P < 0.001). Fertility rate in the
nonaqueous group differed statistically from that of the
control group in 2012 (odds ratio 95% CI ¼ [24.5, 1],
P < 0.001) and 2013 (odds ratio 95% CI ¼ [1.0, 428.9],
P ¼ 0.03). In 2013, however, the difference was quite small
biologically (nonaqueous group ¼ 0.76 foals/F, control
¼ 0.97 foals/F), and we judged that the BLM would not
find the small reduction in foaling due to contraception to be
of interest. Having no reason to suspect that drug
performance would improve in subsequent years and not
wanting to contribute foals unnecessarily to the off-range
population of BLM horses, we removed the nonaqueous
group from the experiment at the end of the second foaling
season. The fact that few treated animals were fertile in the
first year indicates that the time we allowed between
vaccination and introduction of the males (2 months) was
sufficient for contraceptive efficacy to develop.
We used logistic regression to model probability of foaling
in the aqueous and nonaqueous treatment groups in 2012
and 2013. Our initial model contained the potential
explanatory variables treatment, year, and a treatment by
year interaction. Of these, only year was significant
(z ¼ 2.675, P ¼ 0.007), consistent with the fact that the
fertility rate increased in both groups in 2013. Addition of
body condition at the time of treatment did not improve the
model (DAIC ¼ 0.96).
Mean recorded PZP antibody titers reached a maximum
more quickly for the nonaqueous formulation, but also
declined more quickly and were consistently lower than
means for the aqueous formulation after 6 July 2011 (Fig. 1).
A similar pattern was apparent in the number of females that
exhibited their maximum recorded titer on each sampling
date (Table 2). Greater than half of the 30 females treated
with the nonaqueous formulation exhibited their maximum
recorded titer on 3 May 2011, and 29 of the 30 did so by 6
July 2011. In contrast, individual females treated with the
aqueous formulation exhibited their maximum titers over a
longer period of time. Across 11 sampling dates postvaccination, mean PZP titers were 33.7–91.9% greater in
nonpregnant females than in pregnant females in the
aqueous treatment group (Fig. 2A) and 7.8–82.8% greater
in the nonaqueous group (Fig. 2B). The relationship

120
100

Control
Aqueous SpayVac
Nonaqueous SpayVac

80
60
40
20

1 Jul 2011
1 Jul 2012
1 Jul 2013
1 Jan 2013
1 Jan 2012

Date
Figure 1. Mean porcine zona pellucida antibody titers, expressed as % of a
positive reference, in adult female feral horses enrolled in a captive breeding
trial of the immunocontraceptive SpayVac at Pauls Valley, Oklahoma, USA,
2012–2014. Aqueous and nonaqueous refer to 2 different formulations of
SpayVac. Vertical bars represent 1 standard error.
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Table 2. Number of adult female feral horses for which maximum
antibody titers were recorded on each sampling date in a captive breeding
trial of the immunocontraceptive SpayVac at Pauls Valley, Oklahoma,
USA, 2012–2014. Females were treated with either aqueous (n ¼ 30) or
nonaqueous (n ¼ 30) SpayVac on 30 March 2011.
Sampling date

Aqueous SpayVac

Nonaqueous SpayVac

8
6
7
2
5
1
1

17
4
8
0
0
1
0

PZP titer (% of positive reference value)

3 May 2011
7 Jun 2011
6 Jul 2011
2 Aug 2011
7 Sep 2011
5 Oct 2011
14 Dec 2011

A

120

Not pregnant
Pregnant

100
80
60
40
20

1 Jul 2011
1 Jul 2012
1 Jul 2013
1 Jan 2013
1 Jan 2012

DISCUSSION

PZP titer (% of positive reference value)

Date

B

120
100
80
60
40
20

1 Jul 2011

1 Jul 2012
1 Jan 2012
1 Jan 2013

Date
Figure 2. Mean porcine zona pellucida antibody titers, expressed as % of a
positive reference, in pregnant and nonpregnant adult female feral horses
enrolled in a captive breeding trial of the immunocontraceptive SpayVac at
Pauls Valley, Oklahoma, USA, 2012–2014. Aqueous (A) and nonaqueous
(B) refer to 2 different formulations of SpayVac. Vertical bars represent 1
standard error.
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however, did we record a severity score >1 (reaction present,
but no pain or lameness noticeable).
Neither Fisher’s exact test (P ¼ 0.28) nor logistic regression
analysis (deviance ¼ 2.648, df ¼ 2, P ¼ 0.27) revealed an effect
of treatment (control, aqueous vaccine, or nonaqueous
vaccine) on the probability of a female exhibiting a reaction
at the injection site. However, combining control and treated
animals by formulation (aqueous or nonaqueous) in a logistic
regression model revealed a greater (z ¼ 2.183, P ¼ 0.03)
incidence of injection-site reactions in animals receiving the
nonaqueous formulation (41.5%) than in those receiving the
aqueous formulation (19.0%). Interestingly, adding a variable
for presence or absence of PZP did not improve the model
(DAIC ¼ 1.52); that is, reactions were as likely to occur in
animals receiving liposomesþadjuvant as in animals that
received the vaccine with antigen. Addition of body condition
also failed to improve the model (DAIC ¼ 1.91).
On 9 and 10 January 2013, we rectally palpated 59 treated
females (1 F in the nonaqueous treatment group died of
torsion of the small intestine unrelated to the study in Feb
2012). Of those, 25 were open and only 1, treated with the
aqueous vaccine, exhibited slight uterine edema. On 13 and
14 November 2013, we rectally palpated 30 animals treated
with the aqueous vaccine. Of the 17 females that were open,
2, 2, and 1 showed slight, moderate, and extensive uterine
edema, respectively.
Of the 30 females treated with aqueous SpayVac, 5
(numbers 461, 3763, 3904, 4305, and 4330) had progesterone levels consistently <0.5 ng/mL and were thus judged to
be not cycling. None of the 5 was fertile in any of the first
3 years of the study, but they were not the females with the
highest maximum antibody titers (Table 3).

A single-injection contraceptive having multiyear efficacy in
horses would be of great utility to the BLM and other
agencies that manage feral horses. In the only other trial of
SpayVac in horses where pregnancy or foaling was an
endpoint, Killian et al. (2008) reported pregnancy rates in 12
treated adult females of 0% in the first year after vaccination
and 17% in the next 3 years, as compared with pregnancy
rates of 75%, 75%, 88%, and 100% in 8 control females. In
addition, although breeding was not a part of their study,
Bechert et al. (2013) found that 93% of 14 adult females
treated with SpayVac ceased estrous cycling within 3–4
months of vaccination. Thus, both of these earlier studies
offered hope that SpayVac might provide the singleinjection, multiyear efficacy desired by the BLM for
management of wild horses. Although we received all
vaccines frozen, the nonaqueous vaccine was of particular
interest because the lyophilized material could be stored
unfrozen and easily reconstituted with adjuvant in the field,
rather than having to create an emulsion as with the aqueous
version.
We were unable to attain contraceptive efficacy as great as
that reported by Killian et al. (2008). Individual variation in
response to the vaccine may account for some of the
difference between our results and those of Killian et al.
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Table 3. Number of pregnancies and maximum recorded porcine zona pellucida (PZP) antibody titer, expressed as percent of a positive reference, in adult
female feral horses treated with the aqueous formulation of the immunocontraceptive SpayVac in a captive breeding trial at Pauls Valley, Oklahoma, USA,
2012–2014. Females are listed in order of increasing maximum PZP antibody titer.
Female ID number
7802
3908
1688
500
4320
9186
9655
6105
609
8789
3901
394
4124
461
8667

Max. PZP titera

No. of pregnanciesb

Female ID number

Max. PZP titera

No. of pregnanciesb

31.19
37.94
39.66
41.90
44.31
46.33
51.33
56.23
60.11
60.38
69.62
70.60
72.98
73.98
78.12

3
2
3
2
2
1
2
2
0
2
3
1
3
0
2

4305
3904
8816
4257
504
3763
3724
4301
4330
4253
4133
3795
3815
1029
4319

85.00
85.40
86.38
92.69
96.88
99.12
107.74
111.07
111.39
134.79
135.26
137.72
176.06
196.89
297.25

0
0
2
0
0
0
0
0
0
1
0
0
0
0
0

a

PZP antibody titer is expressed as a percentage of a positive reference, represented by a female vaccinated in a previous study and judged to have a strong,
PZP-specific antibody response. The positive reference sample was considered to have a titer of 100%.
b
Pregnancy was determined through hormone assay (pregnant mare serum gonadotropin and estrone sulfate), rectal palpation, and direct observation of foals.
A female was considered pregnant if any of the 3 measures was positive.

(2008); other factors that may be important include dose,
adjuvant, and injection site. Henderson et al. (1988) showed
that dose (amount of PZP administered) can affect both
estrous cyclicity and duration of infertility. In the study by
Killian et al. (2008), each dose contained 400 mg of PZP,
whereas our vaccines and those used by Bechert et al. (2013)
contained only 200 mg of PZP/dose. This change was first
instituted by the manufacturer in the vaccine provided to
Bechert et al. (2013) based on the fact that a primer dose of
65 mg of PZP emulsified with Freund’s Complete Adjuvant
(FCA) followed by a booster dose of 65 mg of PZP
emulsified with Freund’s Incomplete Adjuvant was sufficient
to contracept horses on Assateague Island, Virginia, USA
(Kirkpatrick et al. 1990, 1995). The manufacturer thus
expected that 200 mg of PZP in the liposome formulation
used in SpayVac would be more than sufficient for
contraception. The fact that 93% of females treated by
Bechert et al. (2013) stopped cycling seemed to support that
expectation.
Our choice of adjuvant was influenced by several factors.
First, we were uncertain that AdjuVacTM, which was used by
Killian et al. (2008), would be readily available in the future.
The various versions of Freund’s adjuvants, on the other

Table 4. Percent of treated and control adult female feral horses exhibiting
an injection-site reaction in a captive breeding trial of the
immunocontraceptive SpayVac at Pauls Valley, Oklahoma, USA, 2012–2014.
Females exhibiting a
reaction
Treatment

n

No.

%

Saline control
Aqueous control
Nonaqueous control
Aqueous SpayVac
Nonaqueous SpayVac

6
12
12
30
30

0
1
5
7
12

0
8.3
41.7
23.3
40.0
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hand, are available from several suppliers. Second, MFA is
thought to be less likely to cause injection-site reactions than
FCA. Lyda et al. (2005) showed that antibody titers in adult
females treated with MFAþPZP were greater than those in
females treated with FCAþPZP, although this finding was
not statistically significant. Finally, Bechert et al. (2013)
achieved what appeared to be positive results with SpayVac
formulated with MFA. All of these factors influenced our
choice of MFA as the adjuvant.
In both previous studies of SpayVac in horses, injections
were given in the neck (Killian et al. 2008, Bechert et al.
2013). Although no data were presented, several authors
suggested that reactions to injections given in the rump were
less common and perhaps less severe than to injections given
in the neck, which influenced our decision on injection site
(Lyda et al. 2005, Kirkpatrick et al. 2011, Bechert et al.
2013). Additional work to clarify the relationship between
injection location and reactions may be warranted.
Antibody titers in response to vaccination with PZP have
been shown to vary considerably within a species even when
dose and adjuvant are the same (Kirkpatrick et al. 2011).
Differences in response may to some extent depend on an
animal’s physiological state, but we saw no effect of body
condition on probability of foaling. This is perhaps not
surprising in that body condition ranged only from 4.0 to 6.0
(x ¼ 4.9 for all 90 females) when vaccinations were given in
March of 2011, and improved substantially by March of 2012
(x ¼ 6.6, range ¼ 5.0–8.0).
Comparisons between antibody titers measured in our
study and those reported by Killian et al. (2008) and Bechert
et al. (2013) are difficult because of differences in
measurement scale and units in which titers were quantified.
In general, however, it appears that, for unknown reasons,
high titers were sustained longer in those 2 previous studies
than in ours. Other studies have shown a correlation between
antibody titers and contraception in females, with antibody
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titers 50–60% of a positive reference serum being sufficient to
render 90–95% of adult females infertile (Liu et al. 1989,
2005; Turner et al. 1997). However, none of these studies
were >1 year in duration. Our data suggest that a similar
threshold may exist for multiple-year efficacy in horses
treated with SpayVac. Only a single foal was produced
(female 4253) in 3 years following inoculation in females
having a maximum titer greater than approximately 90% of
the positive reference; we believe that datum may be an error
in foal assignment to a dam, because the female tested
inconclusive for pregnancy by hormone analysis and negative
for pregnancy by palpation in that year. Despite our careful
efforts to associate foals with dams, an occasional error is
possible because many of our females, particularly those with
bay coloration, were very similar in appearance. Titers
reported as a percentage of a positive reference compare
serum taken from a successfully contracepted female (the
positive reference) with sera from other treated and control
females. The lower values reported here, for example in the
control females, were probably below the limit of detection
for the assay and likely reflect background issues, which are
not uncommon when testing for polyclonal antibodies. As
such, most values below approximately 30% of the reference
serum likely do not represent true immune responses, which
may explain the fluctuations in control values through time.
Our study and that of Bechert et al. (2013) clearly showed
that reactions at the injection site were fairly common even
with MFA as adjuvant and, contrary to a previous report
(Roelle and Ransom 2009), even when injections are
delivered by hand rather than by dart. Both studies reported
that reactions can resolve only to reappear at a later time, and
both studies provided some evidence that reactions at the
injection site are attributable to the adjuvant rather than the
immunogen. Increased rates of injection-site reactions in
these 2 studies are most likely the result of more frequent and
closer examination, both visually and by palpation. Interestingly, however, even such close scrutiny does not detect all
reactions. In our study, necropsy of female 740, which died of
torsion of the small intestine, revealed a sterile abscess that
had gone undetected in 7 examinations (visual and by
palpation) over a period of 7 months. It thus seems highly
likely that studies based on field observation alone under
report injection-site reactions. Bechert et al. (2013) found
injection-site reactions to be more frequent for the aqueous
formulation of SpayVac (5/7 ¼ 71.4%) than for the
nonaqueous formulation (3/7 ¼ 42.9%), whereas the reverse
was true in our study. Reasons for this difference are unclear,
but the small sample sizes (n ¼ 7 F/group) in the study by
Bechert et al. (2013) may be a contributing factor. Despite
the fact that injection-site reactions were fairly common in
our study, perhaps the most striking and important
observation was that none of the reactions appeared to be
painful or caused any noticeable change in mobility or gait.
Unlike Killian et al. (2008), we found uterine edema in only
a small proportion of open females in January of 2013, likely
because most of the females were in anestrus. In November of
2013, however, we found uterine edema in a proportion of
females similar to the expected normal frequency (25–30%)
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suggested by Killian et al. (2008) assuming a 21-day estrous
cycle and 5–7 days of the cycle actually in estrus. Our
November examinations should be roughly comparable to
those done by Killian et al. (2008) in mid to late October, so
the reasons that they found much higher rates of uterine
edema remain unclear. We reiterate, however, that we view
the frequencies of uterine edema observed here as normal and
not a contraindication to the use of SpayVac.
Bechert et al. (2013) found that 93% of females treated with
SpayVac ceased cycling 3–4 months after vaccination.
Unfortunately, they were unable to follow the females to
see whether normal ovarian function was restored over time.
We found that 5 of 30 females treated with the aqueous
formulation of SpayVac were not cycling >3 years after
vaccination, which may suggest that loss of ovarian function
is permanent when it occurs. As would be expected, none of
these 5 females was fertile in the first 3 years of our study.
However, an additional 10 females that appeared to be
cycling were also infertile in the first 3 years of our study,
which suggests that some mechanism other than disruption
of ovarian function is responsible for infertility. One
possibility is that antibody titers, even though they declined
significantly following vaccination, were still high enough to
prevent sperm binding to ova in these 10 females.

MANAGEMENT IMPLICATIONS
We did not find SpayVac to be as efficacious as other
investigators have. However, both modeling (Ballou et al.
2008) and field studies (Kirkpatrick and Turner 2008) have
shown that significant reductions in fertility can be achieved
with <100% contraceptive efficacy. If even the modest
results that we observed could be duplicated on a large scale,
which would require registration of SpayVac by the U.S.
Environmental Protection Agency, the BLM and other
agencies charged with managing feral horses would have a
more effective fertility control tool than has heretofore been
available, especially given the fact that no booster inoculation
is required with SpayVac. Concerns about reactions at the
injection site and uterine edema appear to be minimal and
should not deter BLM or others from using SpayVac.
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